NET PROFIT (x1000 EUR)
EMPLOYEES
Infant Bacterial Therapeutics AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
0
|
0
|
26 |
| Earnings before taxes |
-11,919
|
-11,091
|
-5,881 |
| EBITDA |
-12,653
|
-12,132
|
-5,914 |
| Total assets |
20,856
|
31,663
|
31,417 |
| Current assets |
20,077
|
30,783
|
30,466 |
| Current liabilities |
6,033
|
4,162
|
1,610 |
| Equity capital |
14,823
|
27,501
|
29,807 |
| - share capital |
320
|
331
|
275 |
| Employees (average) |
10
|
8
|
7 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
71.1%
|
86.9%
|
94.9% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-57.1%
|
-35.0%
|
-18.6% |
| Current ratio |
332.8%
|
739.6%
|
1892.3% |
| Return on equity (ROE) |
-80.4%
|
-40.3%
|
-19.7% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
2
|
1
|
-1 |
| Chg. No. of employees % |
25%
|
14%
|
-13% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.